Flexion Therapeutics (FLXN) Reports Q4 Loss of $1.97
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Flexion Therapeutics (FLXN) PT Raised to $34.50 at Janney Capital
March 24, 2015 6:34 AM EDTJanney Capital analyst Chiara Russo reiterated a Buy rating and lifted her price target on Flexion Therapeutics (NASDAQ: FLXN) to $34.50 (from $30.00) after the company announced 2014 year end results that were relatively in line with the firm's expectations. Russo also notes Phase... More
